Amgen Inc (AMGN) - מקדם חוב לטווח ארוך להון

This chart of Amgen Inc. (AMGN) asset value demonstrates a current level of 4.77. The company's pricing power is complicated by the need to provide significant rebates to insurers due to the loss of exclusivity for several products. The business relies on a powerful R&D division creating cutting-edge gene and targeted therapies, while financial stability depends on the timely launch of innovative biologics and the protection of its patent portfolio.

This ratio is calculated as the proportion of liabilities with a maturity exceeding one year to total equity, measuring the extent to which long-term financing depends on internal resources. This allows for an assessment of the stability of Amgen Inc. (AMGN) during its expansion into cardiology and rare diseases, where the current long-term debt-to-equity trend confirms Robert Bradway's balanced policy regarding the acquisition of biotech assets.